Royalty Pharma：FDA 核准 Cytokinetics 的 MYQORZO (aficamten) 用於 oHCM

FDA 已核准 MYQORZO (aficamten) 用於有症狀的阻塞性肥厚型心肌病之 NDA。Royalty Pharma 現可就銷售額達 50 億美元以下部分收取 4.5% 權利金，超過部分收取 1%，另加 2.75 億美元已提取資金於 10 年內 1.9 倍償還。Cytokinetics 可能在 12 個月內再提取 1.75 億美元，觸發進一步 1.9 倍償還。

關鍵事實

申報時間: 2025年12月22日下午04:37
事件: FDA 核准
方向: 正面
公司: RPRXRoyalty Pharma
資產: aficamten
來源: SEC 8-K
可信度: 有出處

來源摘錄

8-K NY false 0001802768 0001802768 2025-12-19 2025-12-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Royalty Pharma plc (Exact Name of Registrant as Specified in its Charter) England and Wales 001-39329 98-1535773 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Identification No.) 110 East 59 th Street New York , New York 10022 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (212) 883-0200 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if

SEC 8-K